Here's What We Expect From AbbVie's Immunology Segment in Q4

AbbVie’s immunology franchise, led by Skyrizi and Rinvoq, is driving a return to top-line growth despite Humira’s U.S. loss of exclusivity; Zacks estimates Skyrizi sales of $4.87 billion and Rinvoq sales of $2.33 billion for the to-be-reported quarter, with Q4 and full-year 2025 results due Feb. 4, 2025. Management momentum from new indications (Skyrizi in UC, Rinvoq in GCA) and expansion in neuroscience and oncology underpin expectations, while the stock trades at a forward P/E of 15.50 versus the industry at 17.91; Zacks’ 2025 EPS estimate moved slightly lower to $10.64 (from $10.73) and the shares carry a Zacks Rank #3.

Analysis

Market structure: AbbVie (ABBV) is the primary beneficiary as Skyrizi ($4.87B est. for the quarter) and Rinvoq ($2.33B) offset Humira LOE; payors and biosimilar makers are the principal losers if ABBV keeps pricing power. Expect incremental share gains in IBD and AD to compress pricing elasticity for incumbents (JNJ, LLY) over 12–24 months, while demand-side strength favors large-cap pharma credit (spread tightening) and raises implied vol into the Feb 4 earnings event.

Risk assessment: Key tail risks are FDA or payer safety/restriction actions on JAK inhibitors (class-level alerts), adverse surprises in Skyrizi/Rinvoq uptake, or accelerated biosimilar Humira penetration; any of these could trigger >15% downside in 1–3 months. Immediate catalyst is Feb 4 Q4 print; short-term (weeks–months) risks center on formulary decisions and guidance; long-term (years) depends on label expansions, pipeline readouts and patent litigation outcomes.

Trade implications: Favor tactical exposure to ABBV but manage event IV: initiate a small 2–3% long pre-earnings and use 60–120 day call spreads to express upside while capping premium; consider selling 90-day OTM puts at ~5–8% below current to accumulate if assigned. Relative value: long ABBV vs short JNJ (ratio ~1:0.7) to play immunology share shift; rotate into large-cap pharma and reduce small-cap immunology beta.

Contrarian angles: Consensus underweights persistent Rinvoq momentum from new GCA/CD approvals and may be too focused on Humira LOE; the market may underprice ABBV’s ability to grow revenue mid-single digits even with Humira erosion. Conversely, the market could also be underestimating payer pushback—if formulary exclusions accelerate, ABBV re-rating could reverse quickly, creating asymmetric outcomes for volatility sellers.

Key Decisions for Investors

• Establish a 2–3% long position in ABBV ahead of the Feb 4 Q4 print to capture upside from Skyrizi/Rinvoq momentum; if ABBV beats and guidance is raised, add to 4–6% within 10 trading days; if ABBV misses and drops >5%, scale to 6% target at the pullback.
• Implement a 60–120 day ABBV call spread sized to 1–2% portfolio risk (targeting 8–12% absolute upside) to express bullish view while limiting exposure to earnings IV; alternatively, sell 90-day OTM puts ~5–8% below spot to accumulate stock at a discount and collect premium.
• Execute a pair trade: long ABBV 2% / short JNJ 1.4% (approx 0.7x hedge) to express immunology share gains and valuation compression; rebalance after 90 days or on material AbbVie guidance change.
• Monitor two specific items over the next 30–60 days and act accordingly: (a) FDA/payer safety communications on JAK inhibitors (Rinvoq) — close longs or hedge if a class warning is issued; (b) major PBM/formulary moves for Skyrizi/Rinvoq — widen hedges if AbbVie loses national formulary access.